MA48486B1 - Polymères liant les protons pour administration orale - Google Patents

Polymères liant les protons pour administration orale

Info

Publication number
MA48486B1
MA48486B1 MA48486A MA48486A MA48486B1 MA 48486 B1 MA48486 B1 MA 48486B1 MA 48486 A MA48486 A MA 48486A MA 48486 A MA48486 A MA 48486A MA 48486 B1 MA48486 B1 MA 48486B1
Authority
MA
Morocco
Prior art keywords
proton
oral administration
binding polymers
animal
human
Prior art date
Application number
MA48486A
Other languages
English (en)
Other versions
MA48486A (fr
Inventor
Gerrit Klaerner
Eric F Connor
Randi K Gbur
Matthew J Kade
Paul H Kierstead
Jerry M Buysse
Michael J Cope
Kalpesh N Biyani
Son H Nguyen
Scott M Tabakman
Original Assignee
Tricida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tricida Inc filed Critical Tricida Inc
Publication of MA48486A publication Critical patent/MA48486A/fr
Publication of MA48486B1 publication Critical patent/MA48486B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F26/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F271/00—Macromolecular compounds obtained by polymerising monomers on to polymers of nitrogen-containing monomers as defined in group C08F26/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2810/00—Chemical modification of a polymer
    • C08F2810/20—Chemical modification of a polymer leading to a crosslinking, either explicitly or inherently
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
    • C08J2333/24—Homopolymers or copolymers of amides or imides
    • C08J2333/26—Homopolymers or copolymers of acrylamide or methacrylamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions pharmaceutiques et méthodes de traitement d'un animal, y compris un être humain, et méthodes de préparation de telles compositions. Les compositions pharmaceutiques contiennent des polymères d'amine réticulés et peuvent être utilisées, par exemple, pour traiter des maladies ou d'autres conditions métaboliques dans lesquelles l'élimination des protons et / ou des ions chlorure du tractus gastro-intestinal fournirait des avantages physiologiques tels que la normalisation des concentrations sériques de bicarbonate et du ph sanguin. Chez un animal, y compris un humain.
MA48486A 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale MA48486B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462090287P 2014-12-10 2014-12-10

Publications (2)

Publication Number Publication Date
MA48486A MA48486A (fr) 2020-01-15
MA48486B1 true MA48486B1 (fr) 2021-03-31

Family

ID=55080167

Family Applications (3)

Application Number Title Priority Date Filing Date
MA053106A MA53106A (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale
MA41150A MA41150B1 (fr) 2014-12-10 2015-12-10 Polymères de liaison aux protons pour administration orale
MA48486A MA48486B1 (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA053106A MA53106A (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale
MA41150A MA41150B1 (fr) 2014-12-10 2015-12-10 Polymères de liaison aux protons pour administration orale

Country Status (26)

Country Link
US (3) US11311571B2 (fr)
EP (3) EP3593808B1 (fr)
JP (5) JP6903576B2 (fr)
KR (3) KR20260017508A (fr)
CN (2) CN107428955B (fr)
AU (2) AU2015360413B2 (fr)
BR (2) BR122021001914B1 (fr)
CA (4) CA3205149C (fr)
CY (2) CY1122928T1 (fr)
DK (2) DK3229816T3 (fr)
ES (2) ES2857177T3 (fr)
HR (2) HRP20200689T1 (fr)
HU (2) HUE052736T2 (fr)
IL (4) IL290729B2 (fr)
LT (2) LT3229816T (fr)
MA (3) MA53106A (fr)
MD (2) MD3229816T2 (fr)
ME (1) ME03783B (fr)
MX (3) MX382077B (fr)
PL (2) PL3229816T3 (fr)
PT (2) PT3229816T (fr)
RS (2) RS61409B1 (fr)
RU (2) RU2713416C2 (fr)
SI (2) SI3229816T1 (fr)
SM (2) SMT202000225T1 (fr)
WO (1) WO2016094685A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003327B1 (fr) 2013-06-05 2017-08-09 Tricida Inc. Polymères liant les protons pour administration orale
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
EP3564292B1 (fr) 2016-12-28 2021-06-16 FUJIFILM Corporation Émulsion de polymère contenant des atomes d'azote ou d'un sel de celui-ci, procédé de production s'y rapportant et procédé de production de particules
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
AU2018360868B2 (en) * 2017-11-03 2025-01-02 Tricida, Inc. Method of treating acid-base disorders
CA3080651A1 (fr) 2017-11-03 2019-05-09 Tricida, Inc. Compositions et methode pour traiter des troubles acide-base
CA3102765A1 (fr) * 2018-06-04 2019-12-12 Tricida, Inc. Methode de traitement de troubles de l'equilibre acido-basique
WO2019236124A1 (fr) * 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement de troubles de l'équilibre acido-basique
IL305604A (en) 2021-03-01 2023-11-01 Tricida Inc Pharmaceutical preparations of cross-linked poly(allylamine) polymer
SI4053179T1 (sl) 2021-03-01 2026-01-30 Renosis, Inc. Farmacevtski sestavki iz premreženega poli(alilaminskega) polimera

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01100164A (ja) * 1987-10-12 1989-04-18 Shionogi & Co Ltd スルファモイル−２−ベンゾフランカルボン酸誘導体
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5556619A (en) * 1992-08-20 1996-09-17 The Du Pont Merck Pharmaceutical Company Crosslinked polymeric ammonium salts
CA2202397C (fr) 1994-10-17 2002-07-16 Peter W. Stacpoole Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et procedes de traitement de troubles metaboliques et cardiovasculaires
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
JP3952223B2 (ja) * 1997-05-28 2007-08-01 日東紡績株式会社 アリルアミン重合体
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
EA003095B1 (ru) * 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов
WO1999040990A1 (fr) 1998-02-17 1999-08-19 University Of Maryland Polymeres a fixation d'anions et leur utilisation
US6485703B1 (en) 1998-07-31 2002-11-26 The Texas A&M University System Compositions and methods for analyte detection
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
AU2001241076A1 (en) 2000-03-09 2001-09-17 Hisamitsu Pharmaceutical Co. Inc. Crosslinked anion-exchange resin or salt thereof
WO2001066607A1 (fr) 2000-03-09 2001-09-13 Hisamitsu Pharmaceutical Co., Inc. Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant
US20030091530A1 (en) 2000-03-13 2003-05-15 Takeshi Goto Preventives and/or remedies for hyperphosphatemia
JP2002028737A (ja) 2000-07-07 2002-01-29 Fujitsu Ltd プレス打ち抜き加工方法及びプレス打ち抜き加工装置
DE60212819T2 (de) 2001-04-18 2006-11-23 Genzyme Corp., Cambridge Salzformarme polyallylamine
WO2002085381A1 (fr) 2001-04-18 2002-10-31 Genzyme Corporation Methode pour traiter la goutte et pour fixer l'acide urique
CA2478599A1 (fr) 2002-03-11 2003-09-18 Novartis Ag Sels de nateglinide
CN1671380B (zh) * 2002-08-02 2010-05-26 泰博特克药品有限公司 广谱2-氨基-苯并噻唑磺酰胺类hiv蛋白酶抑制剂
WO2004069866A1 (fr) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Molecules therapeutiques
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
WO2004113872A2 (fr) * 2003-06-24 2004-12-29 The Trustees Of Columbia University In The City Of New York Procedes covalents d'immobilisation de biomolecules thiolees sur des surfaces siliceuses et metalliques
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
CA2551528A1 (fr) 2003-12-31 2005-07-21 Genzyme Corporation Agents sequestrants des acides biliaires a base de polymeres d'amine aliphatique a revetement gastro-resistant
KR20060128972A (ko) 2004-01-29 2006-12-14 각고호우징 게이오기주크 적혈구 기능 수식 물질
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
BRPI0509365B8 (pt) 2004-03-30 2021-05-25 Ilypsa Inc composição farmacêutica, kit farmacêutico, e, uso da referida composição
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
US8501676B2 (en) 2004-07-19 2013-08-06 N.V. Nutricia Preparation for use of aspartate for regulating glucose levels in blood
DE102004035808A1 (de) 2004-07-21 2006-03-16 Kasch, Helmut, Dr. Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20070293429A1 (en) 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US20080214440A1 (en) 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
US20080200533A1 (en) 2005-07-04 2008-08-21 Ramu Krishnan Drug or Pharmaceutical Compounds and a Preparation Thereof
CA2619591C (fr) 2005-08-18 2020-03-24 Globoasia, Llc Composes organiques ferriques, utilisations desdits composes et procedesde fabrication associes
US8986669B2 (en) 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
WO2007038801A2 (fr) 2005-09-30 2007-04-05 Ilypsa, Inc. Compositions de liaison aux cations monovalents comprenant des particules coeur-ecorce avec des ecorces polyvinyliques reticulees et procedes pour les utiliser
WO2007041569A1 (fr) 2005-09-30 2007-04-12 Ilypsa, Inc. Methodes et compositions permettant d'eliminer selectivement des ions potassium du tube digestif d'un mammifere
BRPI0616603A2 (pt) 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma
WO2007055044A1 (fr) 2005-11-08 2007-05-18 Ajinomoto Co., Inc. Agent facilitant le reveil apres une anesthesie
EP1945196A2 (fr) 2005-11-08 2008-07-23 Genzyme Corporation POLYMERES CONTENANT DU MAGNESIUM POUR l'HYPERPHOSPHATEMIE
ITMI20052461A1 (it) 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
RU2008136081A (ru) 2006-02-14 2010-03-20 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтические составы с алифатическими аминными полимерами и способы их производства
EP2016114A2 (fr) 2006-05-05 2009-01-21 Genzyme Corporation Polymères de condensation d'amines comme agents séquestrants de phosphates
EP2043627A2 (fr) 2006-07-05 2009-04-08 Genzyme Corporation Traitements contenant du fer(ii) pour l'hyperphosphatémie
US20100124542A1 (en) 2006-07-18 2010-05-20 Genzyme Corporation Amine dendrimers
WO2008016729A1 (fr) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions pour administration intranasale d'insuline humaine et leurs utilisations
US7964182B2 (en) 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
EP2068819A4 (fr) 2006-09-01 2011-04-20 Genzyme Corp Compositions de dendrimères
CA2749074A1 (fr) 2006-09-01 2008-05-29 Usv Limited Procede de preparation d'hydrochlorure de sevelamer et formulation de celui-ci
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
EP2066293A2 (fr) 2006-09-29 2009-06-10 Genzyme Corporation Compositions dendrimères d'amide
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
JP2010519298A (ja) 2007-02-23 2010-06-03 ゲンズイメ コーポレーション アミンポリマー組成物
US20080207766A1 (en) 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
JP2010520285A (ja) 2007-03-08 2010-06-10 ゲンズイメ コーポレーション スルホンポリマー組成物
TWI445540B (zh) 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
US20100166696A1 (en) 2007-04-27 2010-07-01 Dhal Pradeep K Amido-amine dendrimer compositions
US8273384B2 (en) 2007-07-02 2012-09-25 Stephen Ray Wurzberger Process for the preparation of a non-corrosive base solution and methods of using same
KR20100045965A (ko) 2007-07-11 2010-05-04 도레이 카부시키가이샤 가교 폴리알릴아민 또는 그 산부가염 및 그 의약 용도
EP2016947A1 (fr) 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Nouveau processus à une étape pour préparer des polymères poly(allylamine) réticulés
WO2009023544A2 (fr) 2007-08-10 2009-02-19 Ilypsa, Inc. Compositions pharmaceutiques à base de polymères échangeurs d'anions en dose
US20090125433A1 (en) * 2007-11-13 2009-05-14 Franck Rene Mikulecz Best pre-match routing (of foreign exchange orders)
US20090156647A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Method for maintaining physiological pH levels during intensive physical exercise
PA8807201A1 (es) 2007-12-14 2009-07-23 Genzyme Corp Composiciones farmaceuticas
EP2217215A1 (fr) 2007-12-14 2010-08-18 Genzyme Corporation Compositions pharmaceutiques enrobées
WO2009097127A1 (fr) 2008-01-31 2009-08-06 Genzyme Corporation Compositions pharmaceutiques
JP2009179724A (ja) * 2008-01-31 2009-08-13 Toray Ind Inc 架橋ポリビニルアミン又はその酸付加塩、及びその医薬用途
EP2282729A1 (fr) 2008-03-11 2011-02-16 Livionex Inc. Procédés et compositions pour traiter une inflammation et des pathologies en relation avec une inflammation
AU2009235024A1 (en) * 2008-04-08 2009-10-15 Usv Limited Process for preparation of amine polymer salt
US20110112445A1 (en) 2008-04-11 2011-05-12 GP Investmenti S.r.l Handpiece for Ultrasound Treatments of Human Tissue
WO2009154747A1 (fr) 2008-06-20 2009-12-23 Genzyme Corporation Compositions pharmaceutiques
DE102008030046A1 (de) 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20100008988A1 (en) 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010022381A1 (fr) 2008-08-22 2010-02-25 Relypsa, Inc. Traitement d'une hyperkaliémie par des polymères d'échange de cation réticulés ayant des propriétés physiques améliorées
US8337824B2 (en) 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
KR20110066952A (ko) 2008-09-25 2011-06-17 비브 나노, 인코포레이티드 중합체 나노입자 및 활성 성분의 제형을 제조하는 방법
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
WO2010059384A1 (fr) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Procédé de préparation de dérivés de pyridine tri-substituée et de pyrimidine tri-substituée utiles comme agonistes du récepteur du peptide insulinotrope glucose-dépendant
US20100166861A1 (en) 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
MX381407B (es) * 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
EP2389168A2 (fr) 2009-01-22 2011-11-30 USV Limited Compositions pharmaceutiques comprenant un polymère liant le phosphate
WO2011059609A2 (fr) 2009-10-13 2011-05-19 The Regents Of The University Of Michigan Compositions de dendrimères et procédés de synthèse
EP2490675B1 (fr) 2009-10-22 2019-01-23 Synthon B.V. Composition pharmaceutique comprenant sevelamer
JP5984675B2 (ja) 2009-12-07 2016-09-06 アイアンウッド ファーマシューティカルズ インコーポレイテッド 胃腸障害の療法
CN105017481B (zh) * 2010-02-24 2018-10-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
CN102858347B (zh) 2010-02-24 2016-11-02 瑞立普萨公司 用作胆汁酸螯合剂的聚咪唑
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
KR101238210B1 (ko) 2011-06-30 2013-03-04 엘지전자 주식회사 이동 단말기
US20130137772A1 (en) 2011-11-29 2013-05-30 Raymond J. Bergeron Hydroxypolyamine salts
US20130345303A1 (en) 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients
KR20210005314A (ko) 2012-10-08 2021-01-13 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제
EP3003327B1 (fr) 2013-06-05 2017-08-09 Tricida Inc. Polymères liant les protons pour administration orale
EP3747432A1 (fr) 2013-11-04 2020-12-09 Keryx Biopharmaceuticals, Inc. Citrate ferrique pour réduire l'insuffisance cardiaque chez des patients souffrant d'une maladie rénale chronique
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
AU2018360868B2 (en) 2017-11-03 2025-01-02 Tricida, Inc. Method of treating acid-base disorders
CA3080651A1 (fr) 2017-11-03 2019-05-09 Tricida, Inc. Compositions et methode pour traiter des troubles acide-base
CA3102765A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Methode de traitement de troubles de l'equilibre acido-basique
WO2019236639A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement des troubles de l'équilibre acido-basique
WO2019236124A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement de troubles de l'équilibre acido-basique
US20200306209A1 (en) 2019-03-27 2020-10-01 Tricida, Inc. Method of treating acid-base disorders

Also Published As

Publication number Publication date
RS60208B1 (sr) 2020-06-30
HUE049057T2 (hu) 2020-08-28
LT3593808T (lt) 2021-02-25
HUE052736T2 (hu) 2021-05-28
CN113855703A (zh) 2021-12-31
CA2969238C (fr) 2023-10-17
JP2024164031A (ja) 2024-11-26
HK1243952A1 (en) 2018-07-27
JP7258087B2 (ja) 2023-04-14
RU2020102937A (ru) 2020-02-13
JP6903576B2 (ja) 2021-07-14
CA3164664C (fr) 2025-11-18
CY1124073T1 (el) 2022-05-27
KR20260017508A (ko) 2026-02-05
CA3164664A1 (fr) 2016-06-16
IL290729B2 (en) 2025-12-01
IL278034B (en) 2022-04-01
MX2017007497A (es) 2017-10-04
MA48486A (fr) 2020-01-15
PT3229816T (pt) 2020-05-11
PL3229816T3 (pl) 2020-09-21
PL3593808T3 (pl) 2021-06-14
ES2787218T3 (es) 2020-10-15
RU2017124157A (ru) 2019-01-10
JP2017538822A (ja) 2017-12-28
DK3593808T3 (da) 2021-02-01
CA3205149C (fr) 2026-02-24
EP3593808B1 (fr) 2020-12-09
EP3718551A1 (fr) 2020-10-07
IL322207A (en) 2025-09-01
CN107428955A (zh) 2017-12-01
SMT202000700T1 (it) 2021-01-05
DK3229816T3 (en) 2020-04-27
AU2021245144A1 (en) 2021-11-04
JP2021176971A (ja) 2021-11-11
SMT202000225T1 (it) 2020-05-08
MX2021004558A (es) 2022-05-03
AU2021245144B2 (en) 2024-01-11
RU2713416C2 (ru) 2020-02-05
MA53106A (fr) 2021-09-15
CA3280357A1 (en) 2025-10-30
ME03783B (fr) 2021-04-20
PT3593808T (pt) 2021-02-11
CA2969238A1 (fr) 2016-06-16
EP3229816B1 (fr) 2020-02-05
IL252439A0 (en) 2017-07-31
IL252439B (en) 2020-10-29
AU2015360413A1 (en) 2017-06-08
MX2019014711A (es) 2020-02-12
CY1122928T1 (el) 2021-10-29
MX382077B (es) 2025-03-13
MA41150B1 (fr) 2020-06-30
JP2023085428A (ja) 2023-06-20
AU2015360413B2 (en) 2021-07-08
EP3593808A1 (fr) 2020-01-15
US11738041B2 (en) 2023-08-29
KR20240008418A (ko) 2024-01-18
MD3593808T2 (ro) 2021-05-31
JP6921276B2 (ja) 2021-08-18
BR112017011838B1 (pt) 2023-04-25
EP3229816A1 (fr) 2017-10-18
MA41150A (fr) 2017-10-18
CN113855703B (zh) 2025-11-25
CN107428955B (zh) 2021-09-21
JP2020158530A (ja) 2020-10-01
HRP20200689T1 (hr) 2020-07-24
MX377154B (es) 2025-03-07
IL290729B1 (en) 2025-08-01
JP7536343B2 (ja) 2024-08-20
EP3718551B1 (fr) 2026-02-04
US20230405043A1 (en) 2023-12-21
HRP20210204T1 (hr) 2021-03-19
IL290729A (en) 2022-04-01
US20220339186A1 (en) 2022-10-27
KR20170095269A (ko) 2017-08-22
US20180021370A1 (en) 2018-01-25
MD3229816T2 (ro) 2020-07-31
EP3718551C0 (fr) 2026-02-04
IL278034A (en) 2020-11-30
SI3229816T1 (sl) 2020-09-30
WO2016094685A1 (fr) 2016-06-16
ES2857177T3 (es) 2021-09-28
KR102625115B1 (ko) 2024-01-12
SI3593808T1 (sl) 2021-03-31
CA3205149A1 (fr) 2016-06-16
BR122021001914B1 (pt) 2024-02-27
RU2017124157A3 (fr) 2019-07-17
RS61409B1 (sr) 2021-03-31
LT3229816T (lt) 2020-05-25
BR112017011838A2 (pt) 2017-12-26
US11311571B2 (en) 2022-04-26
KR102920551B1 (ko) 2026-02-02

Similar Documents

Publication Publication Date Title
MA48486B1 (fr) Polymères liant les protons pour administration orale
MY197091A (en) Compositions for treating acid-base disorders
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
RU2009119225A (ru) Способ лечения и профилактики кокцидиозов норок
UA111587C2 (uk) Сполуки для лікування захворювань, пов'язаних з амілоїдними або амілоїдоподібними білками
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
MA38521B1 (fr) Formulation d'acétate d'abiratérone utilisé dans le traitement du cancer de la prostate resistant a la castration
FR3023166B1 (fr) Utilisation d'une composition pharmaceutique renfermant une pectine a titre de principe actif, dans la prevention et/ou le traitement des lesions cutanees impliquant un caractere inflammatoire
AR107734A1 (es) Métodos de tratamiento de diarrea en animales no humanos, neonatales y jóvenes, pre-destete
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
UA102651U (uk) Спосіб корекції ферментної системи антиоксидантного захисту організму глибокотільних корів за ендотоксикозу
RU2013139184A (ru) Препарат траметин для лечения желудочно-кишечных болезней телят и способ его применения
TH147172A (th) องค์ประกอบและกระบวนการเตรียมองค์ประกอบสำหรับการป้องกันและการบำบัดการติดเชื้อ hiv